{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:33:41Z","timestamp":1789749221937,"version":"4.0.1"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: To evaluate the feasibility of radioimmunotherapy (RIT) with radiolabeled anti\u2013carcinoembryonic antigen antibodies after complete resection of liver metastases (LM) from colorectal cancer.<\/jats:p>\n               <jats:p>Patients and Methods: Twenty-two patients planned for surgery of one to four LM received a preoperative diagnostic dose of a 131I-F(ab\u2032)2\u2013labeled anti-carcinoembryonic antigen monoclonal antibody F6 (8-10 mCi\/5 mg). 131I-F(ab\u2032)2 uptake was analyzed using direct radioactivity counting, and tumor-to-normal liver ratios were recorded. Ten patients with tumor-to-normal liver ratios of &amp;gt;5 and three others were treated with a therapeutic injection [180-200 mCi 131I\/50 mg F(ab\u2032)2] 30 to 64 days after surgery.<\/jats:p>\n               <jats:p>Results: Median 131I-F(ab\u2032)2 immunoreactivity in patient serum remained at 91% of initial values for up to 96 hours after injection. The main and dose-limiting-toxicity was hematologic, with 92% and 85% grades 3 to 4 neutropenia and thrombocytopenia, respectively. Complete spontaneous recovery occurred in all patients. No human anti-mouse antibody response was observed after the diagnosis dose; however, 10 of the 13 treated patients developed human anti-mouse antibody \u223c3 months later. Two treated patients presented extrahepatic metastases at the time of RIT (one bone and one abdominal node) and two relapsed within 3 months of RIT (one in the lung and the other in the liver). Two patients are still alive, and one of these is disease-free at 93 months after resection. At a median follow-up of 127 months, the median disease-free survival is 12 months and the median overall survival is 50 months.<\/jats:p>\n               <jats:p>Conclusion: RIT is feasible in an adjuvant setting after complete resection of LM from colorectal cancer and should be considered for future trials, possibly in combination with chemotherapy, because of the generally poor prognosis of these patients.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-07-4698","type":"journal-article","created":{"date-parts":[[2008,6,2]],"date-time":"2008-06-02T19:46:02Z","timestamp":1212435962000},"page":"3487-3493","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Adjuvant Radioimmunotherapy Trial with Iodine-131\u2013Labeled Anti\u2013Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab\u2032)2 after Resection of Liver Metastases from Colorectal Cancer"],"prefix":"10.1158","volume":"14","author":[{"given":"Marc","family":"Ychou","sequence":"first","affiliation":[{"name":"1Institut de Recherche en Cance\u0301rologie de Montpellier (IRCM);"},{"name":"2Institut National de la Sante et de la Recherche Medicale U896;"},{"name":"3Universite\u0301 Montpellier1;"},{"name":"4CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Azria","sequence":"additional","affiliation":[{"name":"1Institut de Recherche en Cance\u0301rologie de Montpellier (IRCM);"},{"name":"2Institut National de la Sante et de la Recherche Medicale U896;"},{"name":"3Universite\u0301 Montpellier1;"},{"name":"4CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Menkarios","sequence":"additional","affiliation":[{"name":"4CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France;"},{"name":"7Department of Radiation Oncology, Maisonneuve-Rosemont Hospital, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Faurous","sequence":"additional","affiliation":[{"name":"4CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc\u0327ois","family":"Quenet","sequence":"additional","affiliation":[{"name":"4CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Saint-Aubert","sequence":"additional","affiliation":[{"name":"4CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rouanet","sequence":"additional","affiliation":[{"name":"4CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Pe\u0300legrin","sequence":"additional","affiliation":[{"name":"1Institut de Recherche en Cance\u0301rologie de Montpellier (IRCM);"},{"name":"2Institut National de la Sante et de la Recherche Medicale U896;"},{"name":"3Universite\u0301 Montpellier1;"},{"name":"4CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bascoul-Mollevi","sequence":"additional","affiliation":[{"name":"4CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Guerreau","sequence":"additional","affiliation":[{"name":"5Schering-CIS Biointernational, Gif-sur-Yvette, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Saccavini","sequence":"additional","affiliation":[{"name":"5Schering-CIS Biointernational, Gif-sur-Yvette, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Mach","sequence":"additional","affiliation":[{"name":"6De\u0301partement de Biochimie, Universite\u0301 de Lausanne, Epalinges, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Artus","sequence":"additional","affiliation":[{"name":"4CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre\u0301","family":"Pe\u0300legrin","sequence":"additional","affiliation":[{"name":"1Institut de Recherche en Cance\u0301rologie de Montpellier (IRCM);"},{"name":"2Institut National de la Sante et de la Recherche Medicale U896;"},{"name":"3Universite\u0301 Montpellier1;"},{"name":"4CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,6,2]]},"reference":[{"key":"2022061021354337800_B1","doi-asserted-by":"crossref","unstructured":"Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg\u20081995;19:59\u201371.","DOI":"10.1007\/BF00316981"},{"key":"2022061021354337800_B2","doi-asserted-by":"crossref","unstructured":"Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol\u20081997;15:938\u201346.","DOI":"10.1200\/JCO.1997.15.3.938"},{"key":"2022061021354337800_B3","doi-asserted-by":"crossref","unstructured":"Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin\u20081999;49:231\u201355.","DOI":"10.3322\/canjclin.49.4.231"},{"key":"2022061021354337800_B4","doi-asserted-by":"crossref","unstructured":"Lehnert T, Otto G, Herfarth C. Therapeutic modalities and prognostic factors for primary and secondary liver tumors. World J Surg\u20081995;19:252\u201363.","DOI":"10.1007\/BF00308635"},{"key":"2022061021354337800_B5","doi-asserted-by":"crossref","unstructured":"Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg\u20081997;84:977\u201380.","DOI":"10.1002\/bjs.1800840719"},{"key":"2022061021354337800_B6","doi-asserted-by":"crossref","unstructured":"Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol\u20082006;24:4976\u201382.","DOI":"10.1200\/JCO.2006.06.8353"},{"key":"2022061021354337800_B7","unstructured":"Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery\u20081994;116:703\u201310."},{"key":"2022061021354337800_B8","doi-asserted-by":"crossref","unstructured":"Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol\u20082002;20:2453\u201363.","DOI":"10.1200\/JCO.2002.11.076"},{"key":"2022061021354337800_B9","doi-asserted-by":"crossref","unstructured":"Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol\u20082001;19:3918\u201328.","DOI":"10.1200\/JCO.2001.19.19.3918"},{"key":"2022061021354337800_B10","doi-asserted-by":"crossref","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med\u20082002;346:235\u201342.","DOI":"10.1056\/NEJMoa011795"},{"key":"2022061021354337800_B11","doi-asserted-by":"crossref","unstructured":"Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer\u20082002;94:1373\u201381.","DOI":"10.1002\/cncr.10308"},{"key":"2022061021354337800_B12","doi-asserted-by":"crossref","unstructured":"Liersch T, Meller J, Kulle B, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol\u20082005;23:6763\u201370.","DOI":"10.1200\/JCO.2005.18.622"},{"key":"2022061021354337800_B13","unstructured":"Behr TM, Sharkey RM, Juweid ME, et al. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J Nucl Med\u20081997;38:409\u201318."},{"key":"2022061021354337800_B14","doi-asserted-by":"crossref","unstructured":"Welt S, Divgi CR, Kemeny N, et al. Phase I\/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol\u20081994;12:1561\u201371.","DOI":"10.1200\/JCO.1994.12.8.1561"},{"key":"2022061021354337800_B15","unstructured":"Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody\/streptavidin in patients with metastatic colon cancer. Clin Cancer Res\u20082000;6:406\u201314."},{"key":"2022061021354337800_B16","doi-asserted-by":"crossref","unstructured":"Ychou M, Pelegrin A, Faurous P, et al. Phase-I\/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab\u2032)2 in patients with non-resectable liver metastases from colorectal cancer. Int J Cancer\u20081998;75:615\u20139.","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<615::AID-IJC20>3.0.CO;2-6"},{"key":"2022061021354337800_B17","unstructured":"Hammarstrom S, Shively JE, Paxton RJ, et al. Antigenic sites in carcinoembryonic antigen. Cancer Res\u20081989;49:4852\u20138."},{"key":"2022061021354337800_B18","doi-asserted-by":"crossref","unstructured":"Ychou M, Ricard M, Lumbroso J, et al. Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissues. Eur J Cancer\u20081993;29:1105\u201311.","DOI":"10.1016\/S0959-8049(05)80297-7"},{"key":"2022061021354337800_B19","unstructured":"Buchegger F, Mach JP, Pelegrin A, et al. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. J Nucl Med\u20081995;36:420\u20139."},{"key":"2022061021354337800_B20","doi-asserted-by":"crossref","unstructured":"Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys\u20082000;47:13\u201347.","DOI":"10.1016\/S0360-3016(99)00559-3"},{"key":"2022061021354337800_B21","doi-asserted-by":"crossref","unstructured":"Welt S, Divgi CR, Real FX, et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol\u20081990;8:1894\u2013906.","DOI":"10.1200\/JCO.1990.8.11.1894"},{"key":"2022061021354337800_B22","doi-asserted-by":"crossref","unstructured":"Bertagnolli MM. Radioimmunotherapy for colorectal cancer. Clin Cancer Res\u20082005;11:4637\u20138.","DOI":"10.1158\/1078-0432.CCR-05-0485"},{"key":"2022061021354337800_B23","unstructured":"Sgouros G. Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle. J Nucl Med\u20081995;36:1910\u20132."},{"key":"2022061021354337800_B24","unstructured":"Lygidakis NJ, Sgourakis G, Vlachos L, et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepato-gastroenterology\u20082001;48:1685\u201391."},{"key":"2022061021354337800_B25","unstructured":"Asahara T, Kikkawa M, Okajima M, et al. Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepato-gastroenterology\u20081998;45:805\u201311."},{"key":"2022061021354337800_B26","doi-asserted-by":"crossref","unstructured":"Rudroff C, Altendorf-Hoffmann A, Stangl R, Scheele J. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Kongressbd Dtsch Ges Chir Kongr\u20081999;384:243\u20139.","DOI":"10.1007\/s004230050199"},{"key":"2022061021354337800_B27","doi-asserted-by":"crossref","unstructured":"Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg\u20081998;228:756\u201362.","DOI":"10.1097\/00000658-199812000-00006"},{"key":"2022061021354337800_B28","doi-asserted-by":"crossref","unstructured":"Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol\u20082002;20:1499\u2013505.","DOI":"10.1200\/JCO.20.6.1499"},{"key":"2022061021354337800_B29","doi-asserted-by":"crossref","unstructured":"Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med\u20082005;352:734\u20135.","DOI":"10.1056\/NEJM200502173520723"},{"key":"2022061021354337800_B30","doi-asserted-by":"crossref","unstructured":"Mackay HJ, Billingsley K, Gallinger S, et al. A multicenter phase II study of \u201cadjuvant\u201d irinotecan following resection of colorectal hepatic metastases. Am J Clin Oncol\u20082005;28:547\u201354.","DOI":"10.1097\/01.coc.0000178031.69209.47"},{"key":"2022061021354337800_B31","unstructured":"Wong JY, Shibata S, Williams LE, et al. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res\u20082003;9:5842\u201352."},{"key":"2022061021354337800_B32","doi-asserted-by":"crossref","unstructured":"Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM. Update of carcinoembryonic antigen radioimmunotherapy with (131)i-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol\u20082007;14:2577\u201390.","DOI":"10.1245\/s10434-006-9328-x"},{"key":"2022061021354337800_B33","doi-asserted-by":"crossref","unstructured":"Garambois V, Glaussel F, Foulquier E, et al. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers. BMC Cancer\u20082004;4:75.","DOI":"10.1186\/1471-2407-4-75"},{"key":"2022061021354337800_B34","doi-asserted-by":"crossref","unstructured":"Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol\u20082006;24:823\u201334.","DOI":"10.1200\/JCO.2005.03.8471"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/14\/11\/3487\/1975192\/3487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/14\/11\/3487\/1975192\/3487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T02:40:13Z","timestamp":1654915213000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/14\/11\/3487\/72565\/Adjuvant-Radioimmunotherapy-Trial-with-Iodine-131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2008,6,2]]},"published-print":{"date-parts":[[2008,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-07-4698","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,1]]}}}